

Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

Tel 01865 784980
Fax 08701 671931

16 September 2013

Physiomics plc

("Physiomics") or ("the Company")

Physiomics to present on the cardiac toxicity platform at the 2013 Safety Pharmacology Society's Annual Meeting ("SPS")

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics.

The platform uses readily available lab-based data to predict the risk that drugs in development will have serious cardiac side effects which could lead to drug program closure. Three versions of the model are now available, two to predict outcomes in animal experiments, dog and rabbit, and a third one to predict cardiac liability in humans. Benchmarking tests against state of the art models will be presented in the poster. The results show that the Physiomics model is more predictive than the state of the art models. Furthermore, given that the same structural model is used for making predictions in different species, the model is ideally placed to make translational predictions, i.e. from animal to human.

The abstract #23 ("Predicting Cardiac Toxicity from Data Generated via High-Throughput Screening") will be presented in the "Disease Models, In Silico, Exploratory Pharmacology" session.

More information about the conference may be found at:
<http://www.safetypharmacology.org/am2013/>

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to present the progress of our cardio tox platform at the SPS meeting as part of our roll out of this new service, which has already attracted significant interest from our large pharma partners."

Physiomics plc

Registered in England and Wales Number 4225086

Registered Office: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO
+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell
+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as \$242 million, from the current estimate of around \$800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002